The sustained long-term activity of brigatinib in patients with crizotinib-refractory ALK+ NSCLC was confirmed in the final analysis of ALTA at a median follow-up of 19.6 months (range: 0.1–62.8) in arm A and 28.3 months (range: 0.1–66.8) in arm B, and more than 4 years after the last patient was enrolled. This evidence concerns the gene ALK and non-small cell lung carcinoma.